Recursion Unveils OpenPhenom-S/16: A Foundation Model for Microscopy Data
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) has released OpenPhenom-S/16, a new publicly accessible foundation model, on Google Cloud’s Vertex AI Model …
All Posts
Schrödinger and Novartis Forge Partnership to Scale Computational Drug Discovery
Schrödinger, Inc. (Nasdaq: SDGR) has entered a collaboration and licensing agreement with Novartis to advance drug discovery efforts on multiple …
Recursion Unveils New Foundation Model for Molecular Property Prediction
Recursion researchers have introduced MolE, a new model aimed at improving predictions of chemical and biological properties of molecules by …
AI-Driven Drug Shows Promising Phase IIa Results in Treating Fatal Lung Disease
Insilico Medicine, a biotechnology company that developed foundational artificial intelligence (AI) in drug discovery platform, recently reported promising results from …
AlphaFold3 Goes Open Source
DeepMind released AlphaFold3’s code, available on GitHub, marking a new stage in AI-based protein structure prediction. AlphaFold3 expands the tool's …
Tempus AI to Acquire Ambry Genetics for $600 Million
Tempus AI has announced its acquisition of Ambry Genetics, from KONICA MINOLTA, INC. for $600 million, comprising $375 million in …
BPGbio Presents AI-Guided Immune-Modulating Therapeutics at SITC 2024
BPGbio presented findings at SITC 2024 on two oncology drug candidates, BPM31510 and BRG399, aimed at advancing immune-based cancer treatments.
Tango Therapeutics Shifts Focus from TNG908 to More Promising Cancer Drug Candidates, TNG462 and TNG456
Tango Therapeutics (NASDAQ: TNGX) announced that it is stopping enrollment in its TNG908 clinical trial following disappointing results for glioblastoma, …
Research Grid Raised $6.48M to Drive Automation in Clinical Trials
Research Grid has secured $6.48 million in seed funding, led by Fuel Ventures, with additional support from Arve Capital, Ada …
UK Life Sciences Venture Capital Outperforms General Market: British Business Bank Report
New research from the British Business Bank reveals that life sciences venture capital (VC) funds are delivering higher realized returns …
Cautious Optimism in 2024 for Healthcare M&A
2024 was supposed to mark the start of a significant comeback for healthcare mergers and acquisitions (M&A). Yet with the …
New AI-Enhanced Architecture for EHDS2 Implementation Released
BC Platforms, Modirum Platforms, VEIL.AI, and Productivity Leap have jointly developed a reference architecture to implement the European Health Data …